IndustryCompany release

Insmed Q3 revenue reaches $524.4M as Brinsupri launches in Japan

🇺🇸 INSMED Inc (INSM) · Thu 29 Oct 2026

Insmed lifted the low end of 2026 sales guidance for Brinsupri and Arikayce, while the FDA set a January 2027 PDUFA date for an Arikayce label expansion.

Insmed reported total revenue of $524.4 million for the third quarter of 2026. Brinsupri (brensocatib) contributed $400.1 million and Arikayce added $124.4 million.

The company raised the low end of its full-year 2026 sales guidance for both products. The summary of the results does not give the updated guidance ranges.

In Japan, the Ministry of Health, Labour and Welfare approved Brinsupri in August for non-cystic fibrosis bronchiectasis in patients aged 12 and older. Insmed said the product launched there in October.

On the regulatory side, the US Food and Drug Administration has accepted a supplemental new drug application (sNDA) for Arikayce in Mycobacterium avium complex (MAC) lung disease. The agency granted Priority Review and set a PDUFA goal date of 28 January 2027. As general context, a PDUFA date is the target date by which the FDA aims to complete its review of an application.

What it means for your team

  • Market-access teams should note the Japanese launch of Brinsupri in October, following the August approval for non-cystic fibrosis bronchiectasis in patients 12 and older.
  • Regulatory teams can track 28 January 2027 as the FDA decision target for the Arikayce sNDA in MAC lung disease, reviewed under Priority Review.
  • The upgraded guidance for both products signals continued commercial momentum, though the updated figures were not available in the material reviewed.

Company's press release (SEC filing): INSMED Inc ↗

Article written by VigiEye from the official source (INSMED Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →